Federal Register of Legislation - Australian Government

Primary content

PB 71 of 2022 Other as made
This instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) to add, delete and make changes to drugs, forms, manners of administration, brands, responsible person codes, authorised prescribers, maximum quantities/amounts and repeats and the circumstances for prescribing various pharmaceutical benefits (including authority requirements).
Administered by: Health and Aged Care
Registered 29 Jul 2022
Tabling HistoryDate
Tabled HR01-Aug-2022
Tabled Senate02-Aug-2022
To be repealed 23 Nov 2022
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

 

Commonwealth Coat of Arms of Australia

 

PB 71 of 2022

 

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2022 (No. 7)

 

National Health Act 1953

 

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the National Health Act 1953.

Date                 28 July             2022

 

 

 

 

 

 

 

 

 

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

 

 


Contents

1......... Name............................................................................................................................... 1

2......... Commencement............................................................................................................... 1

3......... Authority......................................................................................................................... 1

4......... Schedules......................................................................................................................... 1

Schedule 1—Amendments                                                                                                                          2

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011
(PB 79 of 2011)
                                                                                                                                      2

 

 

 


1        Name

(1)          This instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2022 (No. 7).

(2)          This instrument may also be cited as PB 71 of 2022.

2        Commencement

(1)          Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 August 2022

1 August 2022

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)               Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3        Authority

This instrument is made under subsection 100(2) of the National Health Act 1953.

4        Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

 

 

 

 


Schedule 1Amendments

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011)

[1]        Schedule 1, Part 1, omit entry for Fotemustine

[2]        Schedule 1, Part 2, entry for Durvalumab

substitute:

Durvalumab

 

1500

4

[3]        Schedule 1, Part 2, omit entry for Fotemustine

[4]        Schedule 3

omit:

SE

Servier Laboratories (Aust.) Pty Ltd

54 004 838 500

[5]        Schedule 4, omit entry for Fotemustine